Navigation Links
ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients
Date:10/21/2007

ine with findings from previous studies.

Event rates from the 2,487 patients in ARRIVE 1 showed improvement from year one to year two with lower rates of all death (2.2%, 5.7% cumulative), Q-wave MI (0.3%, 0.9% cumulative), TAXUS-related TVR (2.5%, 7.6% cumulative) and ARC defined stent thrombosis (0.8%, 2.5% cumulative). The two-year event rates for expanded use patients were comparable to the simpler (TAXUS IV-like) patients with single stent lesions, including ARC stent thrombosis which was equivalent for complex and simple lesion patients at 0.8%.

In the medication-requiring diabetic sub-population (2,054 patients), diabetics had higher rates of death at two years compared to non-diabetics (8.3% vs. 4.6%) but no increase in TAXUS-related TVR (7.6% for both groups). The cumulative rates of Q-wave MI at two years were 0.6% for diabetic patients and 1.0% for non-diabetics. Two-year ARC defined stent thrombosis was 3.2% for diabetics and 2.3% for non-diabetics.

"ARRIVE represents the largest reported series of drug-eluting stent patients in selected high-risk subgroups," said John M. Lasala, M.D., PhD, Professor of Medicine, Washington University School of Medicine. "Considering the complexity of patients studied, the ARRIVE data indicate acceptable TAXUS- related incidence rates observed at one year and favorable safety and performance at two years. The data show consistent outcomes in high-risk patient groups representing a broad spectrum of procedural complexity seen in real-world practice."

"Our extensive ARRIVE registries provide valuable insight into the benefits of the TAXUS Stent in real-world drug-eluting stent use," said Paul LaViolette, Chief Operating Officer of Boston Scientific. "The results are helpful in identifying low frequency TAXUS stent-related events and provide information on expanded use in complex patient populations."

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Indian pharma delegation arrives in Chicago as part of multi-city tour
2. A Positive Selection Assay for Mutation Analysis in Big Blue Animals
3. Epitope-Tagging Vectors for Functional Analysis in Yeast
4. Map and Link Human Genetic Disorders with SSLP Analysis
5. CastAway Precast Gels for Rapid Automated DNA Sequence Analysis
6. Single-cell RT-PCR Analysis of Paramecium Primaurelia with the Eppendorf cMaster RTplusPCR System
7. High-throughput gene expression analysis to screen for anti-asthma drugs
8. Fully automated DNA purification and efficient multiplex PCR for analysis of microsatellite loci
9. Structural Analysis of Glycosylated Peptides in Complex Mixtures with Ion Trap MSn
10. Use of Transcriptor Reverse Transcriptase in Microarray Analysis
11. Increased Sensitivity in Microarray Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014 The first product ... next generation approach to robotics. What sets Droidles completely ... pending technology that allows them to communicate, share code ... over the internet. , “The invention is the system,” ... little Droidles a life of their own, both physically ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 White ... devices, and cloud based eClinical technologies, have been published ... Online. These follow a long line of white papers ... publications including Life Science Leader, Pharmaceutical Online, and OpenHealthNews. ... provided a paper by CTO Marc Desgrousilliers, 'The ...
(Date:7/28/2014)... , July 28, 2014 Sapphire Energy, ... today announced the appointment of biotechnology veteran James ... board of directors. Levine replaces Cynthia ,CJ, Warner, who ... will remain chairman of the company,s board of directors. ... Energy,s mission to deliver commercial scale algae-based fuels has ...
(Date:7/28/2014)... Irvine, CA and Annapolis Junction, MD (PRWEB) July 28, ... commercial and research leader in personalized medicine, will be ... testing services at this year’s International Spine Intervention ... will take place July 30th-August 3rd, at the Hyatt ... is designed to enhance the knowledge and clinical competence ...
Breaking Biology Technology:Droidles, the Social Network of Robots and Open Source Platform for the Internet of Things, Launches for Crowd Funding on IndieGoGo.com 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 3Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2
... CBM ) reports third quarter results for the period ... Reported sales decreased by 14.6%, and excluding the impact ...   Adjusted EBITDA was $8.5 million in the third quarter ... Debt, net of cash was $71.4 million at the end ...
... Life Sciences Holdings, Inc. (OTC Bulletin Board: ... discovery, development and commercialization of novel drugs in the therapeutic ... the Company has been awarded a cash grant under the ... part of the Patient Protection and Affordable Care Act of ...
... (OTC Bulletin Board: CVAT, Berlin & Stuttgart: WTC) proudly announces ... Frankfurt Stock Exchange under the ticket symbol WTC. ... another milestone with the listing on the Frankfurt Stock Exchange ... us gain visibility and support in the European market.  The ...
Cached Biology Technology:Cambrex Reports Third Quarter 2010 Results 2Cambrex Reports Third Quarter 2010 Results 3Cambrex Reports Third Quarter 2010 Results 4Cambrex Reports Third Quarter 2010 Results 5Cambrex Reports Third Quarter 2010 Results 6Cambrex Reports Third Quarter 2010 Results 7Cambrex Reports Third Quarter 2010 Results 8Cambrex Reports Third Quarter 2010 Results 9IRS Awards Cash Grant to Advanced Life Sciences Under the Qualifying Therapeutic Discovery Project 2IRS Awards Cash Grant to Advanced Life Sciences Under the Qualifying Therapeutic Discovery Project 3Listing on Frankfurt Stock Exchange for CTI (http://ctinanotech.com) 2Listing on Frankfurt Stock Exchange for CTI (http://ctinanotech.com) 3
(Date:7/29/2014)... University of Kent has shown for the first time ... breakthrough that could have a major impact on cancer ... Biosciences uncovered the mechanism whereby the physical properties of ... filaments are ,fine-tuned, to undertake different functions. , ... stable, providing a framework for the cell, others are ...
(Date:7/29/2014)... JULY 2014 With thirty days to go and ... FEBS-EMBO 2014 Conference are well underway. The event, a ... (FEBS), EMBO, and the French Society for Biochemistry and ... August to Thursday, 4 September at the Palais des ... is the largest meeting for the life sciences in ...
(Date:7/29/2014)... two of the major disciplines behind Jurassic Park is ... stunning photographs and unique illustrations. , Fossil Insects, by ... incredible preservation and diversity of fossilised insects from around ... fossils can tell us about the ancient and modern ... the mosquito in Jurassic Park, many of the hundreds ...
Breaking Biology News(10 mins):Counting down to FEBS-EMBO 2014 in Paris, France 2Unique images bring fossil insects back to life 2
... Ont., July 12, 2001--Eating nuts every day could help ... to new research from St. Michael,s Hospital and the ... by the journal Diabetes Care , a team ... Toronto Department of Nutritional Sciences; St. Michael,s Hospital Risk ...
... Beach, FL. Research to be presented at the ... of Ingestive Behavior (SSIB), the foremost society for research ... that caffeine added to sugar-sweetened, carbonated beverages teaches adolescents ... amount of caffeine added to an unfamiliar beverage was ...
... Research to be presented at the upcoming annual meeting of ... foremost society for research into all aspects of eating and ... increases our willingness to pay for food, while simultaneously decreasing ... ever wondered about why you are willing to pay more ...
Cached Biology News:A 'nutty' solution to type 2 diabetes management 2
...
Newborn Calf Serum US Origin...
SPDP-Trinitrophenol (TNP) Bovine Serum Albumin...
Acrylamide, 500 g. Assay: > 99.9%, acrylic acid: < 0.001%. Conductivity (35%): < 2 umhos/cm.Risks: 45, 46, 48, 23, 24, 25 ; Safety Precautions: 53, 44. Category: Nucleotides & Enzymes & Biochemicals...
Biology Products: